TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07588672: Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

Sponsor: Polyrizon Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$7,797,000

Rescue Site Savings

+$5,140,500

Unlock Full NCT07588672 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07588672 Rescue Dossier →